Insmed (INSM) Exchange Rate Effect (2016 - 2026)
Insmed (INSM) posted quarterly Exchange Rate Effect of -$553000.0 for Q1 2026, down 161.79% year-over-year from $895000.0 in Q1 2025, and down 8000.0% quarter-over-quarter from $7000.0 in Q4 2025.
Powered by 
Analysis
Insmed (INSM) Exchange Rate Effect (2016 - 2026) Analysis & Trends
Insmed's Exchange Rate Effect history runs 11 years deep, the most recent figure standing at -$553000.0 for Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 161.79% year-over-year to -$553000.0; the TTM figure through Mar 2026 stood at -$517000.0 (down 195.56% YoY), while the FY2025 annual figure was $931000.0, up 171.23% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$553000.0, down from $7000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $2.2 million in Q3 2023, with the low at -$3.4 million in Q2 2023.
- The 5-year median for Exchange Rate Effect is -$553000.0 (2026), against an average of -$127941.2.
- The sharpest annual moves came in 2022 and 2024: Exchange Rate Effect surged 501.08% in 2022, then sank 3186.21% in 2024.
- Insmed's Exchange Rate Effect stood at -$1.1 million in 2022, then jumped by 188.64% to $1.0 million in 2023, then tumbled by 248.42% to -$1.5 million in 2024, then surged by 100.47% to $7000.0 in 2025, then plunged by 8000.0% to -$553000.0 in 2026.
- Business Quant data shows INSM's Exchange Rate Effect at -$553000.0 in Q1 2026, $7000.0 in Q4 2025, and -$976000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -287,000.00 |
| 10 | Incyte | 25.64 Bn | 21.11 Bn | 1.57 Bn | -84,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -287,000.00 |
| Mar 31, 2026 | -553,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | -976,000.00 |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 895,000.00 |
| Dec 31, 2024 | -1.51 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | -688,000.00 |
| Mar 31, 2024 | -953,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 2.17 Mn |
| Jun 30, 2023 | -3.40 Mn |
| Mar 31, 2023 | -29,000.00 |
| Dec 31, 2022 | -1.14 Mn |
| Sep 30, 2022 | 1.85 Mn |
| Jun 30, 2022 | -732,000.00 |
| Mar 31, 2022 | -969,000.00 |
| Dec 31, 2021 | -134,000.00 |
| Sep 30, 2021 | -461,000.00 |